Hewlett Packard Enterprise (HPE) has announced that Lupin Limited, a global pharmaceutical company based in Mumbai, India, has chosen HPE Private Cloud Enterprise to modernize its private cloud infrastructure. The solution will streamline operations and enable Lupin to bring workloads back from the public cloud.
Lupin, an established HPE GreenLake cloud customer, selected the HPE solution to manage IT costs while maintaining a top-tier cloud experience. The partnership will focus on data sovereignty, improved operational efficiency, faster innovation, and greater energy savings. HPE Managed Services will oversee the operation of SAP S/4 HANA on HPE systems and manage network and security protocols within Lupin’s data centers.
“By adopting HPE Private Cloud Enterprise, we are aligning our infrastructure with our business goals, ensuring flexibility, security, and operational efficiency as we grow and continue to deliver high-quality products,” said Ramesh Swaminathan, Executive Director and Global CFO at Lupin. “This move is both strategic and cost-effective.”
Som Satsangi, Senior Vice President and Managing Director of HPE India, added, “Our collaboration with Lupin highlights the value of HPE’s hybrid and private cloud solutions. It underscores our ongoing commitment to providing businesses with innovative cloud solutions that drive growth. As more Indian organizations turn to private cloud, we remain a leader in this transformation.”
Lupin is set to enhance its operational efficiency by leveraging HPE Private Cloud Enterprise, which will allow the company to host core applications in centralized data centers while running edge applications directly at manufacturing locations. This hybrid setup minimizes downtime, streamlines workflows, and boosts productivity. The platform’s templated approach also simplifies deployment and automates provisioning, significantly reducing time spent on repetitive IT tasks.
Data security and compliance are also major wins with the new private cloud infrastructure. By shifting workloads from the public cloud to an on-premises environment, Lupin can ensure tighter control over sensitive information and align more closely with stringent pharmaceutical regulations. With built-in security features, the system provides a fortified environment for managing critical workloads.
The solution also supports faster innovation and greater agility. The scalability and flexibility of the private cloud allow Lupin’s IT teams to rapidly respond to changing business needs and support accelerated development cycles. This, in turn, enables the company to bring treatments to market more quickly, ultimately benefiting patients and strengthening the company’s competitive edge.
Edge computing capabilities at manufacturing sites offer significant improvements in quality control. By processing data locally, Lupin can gain real-time insights into production, leading to better monitoring, quicker decision-making, and improved product consistency. Centralized management combined with local data analysis ensures a balanced approach to oversight and operational autonomy.
Finally, the platform delivers long-term cost and sustainability benefits. By consolidating workloads, Lupin can cut operational expenses and lower its carbon footprint. The usage-based pricing model offers transparency and helps manage budgets effectively, all while supporting the company’s broader environmental goals. These improvements will help Lupin enhance security, efficiency, and innovation across its operations.
HPE is a global leader in technology, focused on creating intelligent solutions that help customers collect, analyze, and act on data seamlessly. The company excels in networking, hybrid cloud, and AI, enabling businesses to innovate and optimize operations.
Lupin is a global pharmaceutical company headquartered in Mumbai, India, with a presence in over 100 markets. Specializing in branded and generic medicines, complex generics, and biotechnology products, Lupin has a strong position in several therapeutic areas, including respiratory, cardiovascular, and women’s health. The company operates 15 manufacturing sites and 7 research centers worldwide.
